Last 12 months
Inside the activity.
0 purchase rows · 15 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2020 Filed Feb 13, 2020 23:33 UTC Amendment |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionCommon Stock | 20,000 | $25.62 | $512,400.00 |
DisclosureSEC source: 0000899243-20-004524 · doc4a.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,499,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F2 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on February 7, 2020, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. Read SEC document |
| January 16, 2020 Filed Jan 17, 2020 21:19 UTC |
Harsanyi ZsoltDirector
|
SaleCommon Stock | 3,435 | $55.00 | $188,925.00 |
DisclosureSEC source: 0001367644-20-000004 · wf-form4_157929595097570.xml · nonDerivative · entry 1 Harsanyi Zsolt · CIK 0001380184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,273 F1 · security: Consists of restricted stock units granted the Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Harsanyi. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 09:21 UTC |
Bailey SueDirector
|
SaleCommon Stock | 8,375 | $53.46 | $447,727.50 |
DisclosureSEC source: 0001367644-19-000069 · wf-form4_157624687889376.xml · nonDerivative · entry 1 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,333 F1 · security: Consists of restricted stock units granted under the Company's stock incentive plan, as amended and restated. F2 · price: The price reported is the weighted average sale price. These shares were sold in multiple transactions in prices ranging from $53.08 to $53.82. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:11 UTC |
Zoon Kathryn CDirector
|
SaleCommon Stock | 1,000 | $54.31 | $54,314.00 |
DisclosureSEC source: 0001367644-19-000063 · wf-form4_157419786844482.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,412 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · price: The price reported is the weighted average sale price. These shares were sold in multiple transactions ranging from $54.24 to $54.34. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 14:52 UTC |
Zoon Kathryn CDirector
|
SaleCommon Stock | 3,082 | $54.15 | $166,884.44 |
DisclosureSEC source: 0001367644-19-000061 · wf-form4_157357032406627.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,412 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Zoon. F3 · price: The price reported is the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $53.69 to $54.72. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 14:51 UTC |
Richard RonaldDirector
|
Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 5,153 | $18.64 Strike: $18.64 | $96,051.92 |
DisclosureSEC source: 0001367644-19-000060 · wf-form4_157357026669636.xml · derivative · entry 3 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,152 Underlying: Common Stock · 5,153 shares Expires 2021-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. The date herein represents the third anniversary date of the grant and the final vesting date. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 14:51 UTC |
Richard RonaldDirector
|
SaleCommon Stock | 5,153 | $60.00 | $309,180.00 |
DisclosureSEC source: 0001367644-19-000060 · wf-form4_157357026669636.xml · nonDerivative · entry 2 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,699 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 14:51 UTC |
Richard RonaldDirector
|
Exercise / conversionCommon Stock | 5,153 | $18.64 | $96,051.92 |
DisclosureSEC source: 0001367644-19-000060 · wf-form4_157357026669636.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 21:44 UTC |
Zoon Kathryn CDirector
|
SaleCommon Stock | 1,509 | $56.12 | $84,692.02 |
DisclosureSEC source: 0001367644-19-000046 · wf-form4_156815185293314.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,494 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:05 UTC |
SARAN ATULEVP, Corp Dev, GC & Secretary
|
Tax withholdingCommon Stock | 1,287 | $44.47 | $57,232.89 |
DisclosureSEC source: 0001591070-19-000002 · wf-form4_156538113546168.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,495 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. Read SEC document |
| May 28, 2019 Filed May 29, 2019 00:18 UTC |
Zoon Kathryn CDirector
|
SaleCommon Stock | 1,376 | $43.39 | $59,702.44 |
DisclosureSEC source: 0001567619-19-012278 · doc1.xml · nonDerivative · entry 2 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,003 F3 · shares: The sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Zoon. F4 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.04 to $43.58, inclusive. Read SEC document |
| May 23, 2019 Filed May 29, 2019 00:18 UTC |
Zoon Kathryn CDirector
|
GrantCommon Stock | 5,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012278 · doc1.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,379 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 23, 2019 Filed May 28, 2019 20:09 UTC |
Bailey SueDirector
|
GrantCommon Stock | 5,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012273 · doc1.xml · nonDerivative · entry 1 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,708 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 23, 2019 Filed May 28, 2019 20:15 UTC |
Hauer Jerome MDirector
|
GrantCommon Stock | 5,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012277 · doc1.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,324 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 23, 2019 Filed May 28, 2019 20:07 UTC |
JOULWAN GEORGE ADirector
|
GrantCommon Stock | 5,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012272 · doc1.xml · nonDerivative · entry 1 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,950 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 23, 2019 Filed May 29, 2019 00:12 UTC |
SULLIVAN LOUIS WDirector
|
GrantCommon Stock | 5,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012276 · doc1.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,466 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 23, 2019 Filed May 29, 2019 00:11 UTC |
Richard RonaldDirector
|
GrantCommon Stock | 5,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012275 · doc1.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,699 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 23, 2019 Filed May 29, 2019 00:10 UTC |
Harsanyi ZsoltDirector
|
GrantCommon Stock | 5,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012274 · doc1.xml · nonDerivative · entry 1 Harsanyi Zsolt · CIK 0001380184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,708 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 08, 2019 Filed May 10, 2019 17:18 UTC |
Strei KatherineEVP, Chief HR Officer
|
Tax withholdingCommon Stock | 237 | $47.49 | $11,255.13 |
DisclosureSEC source: 0001567619-19-010449 · doc1.xml · nonDerivative · entry 1 Strei Katherine · CIK 0001709639 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,188 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| May 08, 2019 Filed May 10, 2019 22:14 UTC |
LINDAHL RICHARD SEVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 759 | $47.49 | $36,044.91 |
DisclosureSEC source: 0001567619-19-010458 · doc1.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,937 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:16 UTC |
Kramer RobertPresident and CEO
|
Tax withholdingCommon Stock | 95 | $47.49 | $4,511.55 |
DisclosureSEC source: 0001567619-19-010448 · doc1.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,394 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| May 07, 2019 Filed May 9, 2019 21:18 UTC |
SULLIVAN LOUIS WDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,893 | $0.00 Strike: $13.37 | $0.00 |
DisclosureSEC source: 0001567619-19-010316 · doc1.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,893 shares Expires 2019-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of options granted under the company's stock incentive plan, as amended and restated. F3 · derivative.exercise_date: The option vested in three equal installments in May 2013, May 2014 and May 2015. Each option represents the right of the reporting person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided by the grant agreement. Read SEC document |
| May 07, 2019 Filed May 9, 2019 21:18 UTC |
SULLIVAN LOUIS WDirector
|
Tax withholdingCommon Stock | 2,135 | $49.41 | $105,490.35 |
DisclosureSEC source: 0001567619-19-010316 · doc1.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,730 F1 · shares: Consists of shares owned by the reporting person and delivered to the issuer to satisfy the reporting person's exercise price for the reported stock option exercise. Read SEC document |
| May 07, 2019 Filed May 9, 2019 21:18 UTC |
SULLIVAN LOUIS WDirector
|
Exercise / conversionCommon Stock | 7,893 | $13.37 | $105,529.41 |
DisclosureSEC source: 0001567619-19-010316 · doc1.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:18 UTC |
Mulligan SeamusDirector
|
GrantCommon Stock | 7,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-007364 · doc1.xml · nonDerivative · entry 1 Mulligan Seamus · CIK 0001536639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,141 F2 · security: Mr. Mulligan and his family, collectively hold an aggregate 100% equity interest in Nerano Pharma Ltd, which in turn is the direct owner of 545,590 shares of the Issuer's common stock. F1 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 21:10 UTC |
Havey AdamEVP, Business Operations
|
SaleCommon Stock | 2,430 | $56.93 | $138,339.90 |
DisclosureSEC source: 0001567619-19-006788 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,240 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| March 04, 2019 Filed Mar 4, 2019 23:39 UTC |
Abdun-Nabi DanielDirector · CEO
|
SaleCommon Stock | 14,565 | $58.11 | $846,328.46 |
DisclosureSEC source: 0001567619-19-006066 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,617 F1 · shares: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. F2 · price: The price reported is the weighted average price. These shares were sold in multiple transactions at prices ranging from $56.74 to $59.66, inclusive. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 23:40 UTC |
Havey AdamEVP, Business Operations
|
SaleCommon Stock | 2,024 | $58.20 | $117,796.80 |
DisclosureSEC source: 0001567619-19-006067 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,670 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| February 28, 2019 Filed Feb 28, 2019 19:29 UTC |
Strei KatherineEVP, Chief HR Officer
|
Tax withholdingCommon Stock | 540 | $58.71 | $31,703.40 |
DisclosureSEC source: 0001567619-19-005676 · doc1.xml · nonDerivative · entry 5 Strei Katherine · CIK 0001709639 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,425 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 00:21 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionRestricted Stock Units · Derivative | 9,722 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · derivative · entry 16 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,681 Underlying: Common Stock · 9,722 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F12 · derivative.exercise_date: On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. F12 · derivative.expiration_date: On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 00:21 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Tax withholdingCommon Stock | 3,826 | $58.71 | $224,624.46 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 9 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479,018 Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 00:21 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionCommon Stock | 9,722 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,482,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 00:21 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
SaleCommon Stock | 6,987 | $58.47 | $408,529.89 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,473,122 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F5 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.54 to $59.25. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 00:35 UTC |
Kramer RobertPresident and COO
|
Tax withholdingCommon Stock | 1,941 | $58.71 | $113,956.11 |
DisclosureSEC source: 0001567619-19-005678 · doc1.xml · nonDerivative · entry 5 Kramer Robert · CIK 0001380956 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,489 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 00:38 UTC |
Havey AdamEVP, Business Operations
|
Tax withholdingCommon Stock | 812 | $58.71 | $47,672.52 |
DisclosureSEC source: 0001567619-19-005679 · doc1.xml · nonDerivative · entry 5 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,713 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 00:03 UTC |
Abdun-Nabi DanielDirector · CEO
|
Tax withholdingCommon Stock | 5,101 | $58.71 | $299,479.71 |
DisclosureSEC source: 0001567619-19-005673 · doc1.xml · nonDerivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,182 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:40 UTC |
Havey AdamEVP, Business Operations
|
SaleCommon Stock | 1,019 | $57.92 | $59,022.31 |
DisclosureSEC source: 0001567619-19-006067 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,694 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F2 · price: The price reported is the weighted average price. These shares were sold in multiple transactions at prices ranging from $57.52 to $58.49, inclusive. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 19:29 UTC |
Strei KatherineEVP, Chief HR Officer
|
Tax withholdingCommon Stock | 387 | $57.98 | $22,438.26 |
DisclosureSEC source: 0001567619-19-005676 · doc1.xml · nonDerivative · entry 4 Strei Katherine · CIK 0001709639 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,965 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:21 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionRestricted Stock Units · Derivative | 9,794 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · derivative · entry 15 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,403 Underlying: Common Stock · 9,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F11 · derivative.exercise_date: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. F11 · derivative.expiration_date: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:21 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Tax withholdingCommon Stock | 2,486 | $57.98 | $144,138.28 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 6 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,480,109 Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:21 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionCommon Stock | 9,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 5 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,482,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:21 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
SaleCommon Stock | 10,369 | $58.24 | $603,890.56 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,801 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F4 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.96 to $59.08. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:35 UTC |
Kramer RobertPresident and COO
|
Tax withholdingCommon Stock | 779 | $57.98 | $45,166.42 |
DisclosureSEC source: 0001567619-19-005678 · doc1.xml · nonDerivative · entry 4 Kramer Robert · CIK 0001380956 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,430 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:38 UTC |
Havey AdamEVP, Business Operations
|
Tax withholdingCommon Stock | 409 | $57.98 | $23,713.82 |
DisclosureSEC source: 0001567619-19-005679 · doc1.xml · nonDerivative · entry 4 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,525 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:03 UTC |
Abdun-Nabi DanielDirector · CEO
|
Tax withholdingCommon Stock | 2,570 | $57.98 | $149,008.60 |
DisclosureSEC source: 0001567619-19-005673 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,283 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 19:29 UTC |
Strei KatherineEVP, Chief HR Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 13,929 | $61.01 Strike: $61.01 | $849,808.29 |
DisclosureSEC source: 0001567619-19-005676 · doc1.xml · derivative · entry 6 Strei Katherine · CIK 0001709639 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,929 Underlying: Common Stock · 13,929 shares Expires 2026-02-25 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 19:29 UTC |
Strei KatherineEVP, Chief HR Officer
|
GrantCommon Stock | 3,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-005676 · doc1.xml · nonDerivative · entry 3 Strei Katherine · CIK 0001709639 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,352 F3 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 19:29 UTC |
Strei KatherineEVP, Chief HR Officer
|
GrantCommon Stock | 3,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-005676 · doc1.xml · nonDerivative · entry 2 Strei Katherine · CIK 0001709639 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,869 F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 19:29 UTC |
Strei KatherineEVP, Chief HR Officer
|
Tax withholdingCommon Stock | 448 | $61.01 | $27,332.48 |
DisclosureSEC source: 0001567619-19-005676 · doc1.xml · nonDerivative · entry 1 Strei Katherine · CIK 0001709639 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,386 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:21 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
GrantStock Options (Right to Buy) · Derivative | 36,053 | $0.00 Strike: $61.01 | $0.00 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · derivative · entry 14 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,053 Underlying: Common Stock · 36,053 shares Expires 2026-02-25 F10 · derivative.exercise_date: On February 26, 2019, Mr. El-Hibri was granted 36,053 stock options vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.